Clinical
Semaglutide vs Tirzepatide: How the Two Compare
Two receptors versus one, different trial outcomes, different prices. A clinical decision, not a shopping one.
Semaglutide and tirzepatide are different medications with different mechanisms, different trial outcomes, and different price floors in the compounded market. This piece compares them on the evidence — and explains why the choice between them is clinical, not a shopping decision.
One receptor versus two
Semaglutide is a GLP-1 receptor agonist — it acts on a single hormone-receptor system involved in appetite and blood-sugar regulation. Tirzepatide acts on two systems, GLP-1 and GIP, which is the mechanistic basis for the claim that it tends to produce greater average weight loss. This dual action is the headline difference and the reason tirzepatide is often positioned as the more potent option.
What the pivotal trials showed
The most-cited weight-management figures come from separate trials: STEP-1 for semaglutide reported roughly 15% average body-weight reduction at the studied dose, while SURMOUNT-1 for tirzepatide reported figures rising above 20% at higher doses. These aren't head-to-head numbers from one trial, and individual results vary widely, but the pattern behind tirzepatide's "more weight loss on average" positioning is real. Both sets of figures describe the approved injectable products at studied doses — not compounded, microdose, or oral versions.
Why tirzepatide costs more in the compounded market
Across the captured compounded market, tirzepatide runs higher than semaglutide at the same providers — roughly $30–$100/month more at the maintenance dose. That price gap reflects the more expensive active ingredient and its positioning, not a guarantee that you'll get the trial outcomes in a compounded form. The compounded price difference tracks the branded difference, but the compounded evidence for either is not the trial evidence.
compounded semaglutide compounded tirzepatide
View chart data as a table
| Provider | Semaglutide | Tirzepatide |
|---|---|---|
| NexLife | $145.00 | $186.00 |
| Mochi Health | $178.00 | $278.00 |
| Join Josie | $194.00 | $233.00 |
| Henry Meds | $197.00 | — |
| Eden | $198.00 | $298.00 |
| Ready Med | $297.00 | $449.00 |
Why this is a clinical decision
Which medication suits you depends on your history, tolerance, other conditions, and how you respond — factors a prescriber weighs, not a price comparison. Tolerability, side-effect profile, and individual response vary, and the "more potent on average" option isn't automatically the right one for a given person. Use the price information to budget once a clinician has helped you choose, not to make the medical choice.
Frequently asked questions
Is tirzepatide better than semaglutide?
On average, trials suggest tirzepatide's dual-receptor action produces greater weight loss, but "better on average" isn't "better for everyone." Individual response, tolerability, and clinical fit vary, and the right choice depends on your history. That's a decision for a prescriber, informed by the evidence but not dictated by the average.
Why does compounded tirzepatide cost more?
Its more expensive active ingredient and premium positioning push its compounded price floor above semaglutide's — roughly $30–$100/month more at maintenance dose across the captured market. The gap reflects ingredient cost and positioning, not a guarantee of the trial outcomes in compounded form.
Can I just pick the cheaper one?
Price is a reason to prefer one only after a clinician has confirmed either is appropriate for you. The two aren't interchangeable — different mechanisms, different side-effect profiles, different individual responses. Choose clinically first, then let price inform the logistics.
Evidence status. Pricing figures are provider-reported or independently calculated as of 2026-07-20, not checkout-verified. Compounded medications are not FDA approved. This article is consumer education, not medical advice. See the methodology for how figures are gated and the public evidence ledger for per-figure sources. Found an error? Use the corrections route.